|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.40 NOK | -1.83% |
|
-6.14% | +55.07% |
| 07-13 | Zelluna Doses First Patient in Phase 1 Cancer Therapy Candidate Trial | MT |
| 07-13 | Zelluna ASA Doses First Solid Tumour Patient with ZI-MA4-1 in the ZIMA-101 Phase 1 trial | CI |
Chart: Technical Analysis
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Bullish | Neutral | Bullish |
| Resistance | 22.8 | 30.5 | 28.7 |
| Spread/Res. | -6.14% | -29.84% | -25.44% |
| Spread/Supp. | +7.00% | +51.71% | +37.21% |
| Support | 20 | 14.11 | 15.6 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- ZLNA Stock
- Charts Zelluna ASA
Select your edition
All financial news and data tailored to specific country editions
